Pyxis Oncology, Inc. () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1288050,
    "name": "Pyxis Oncology, Inc.",
    "stock_name": "Pyxis Oncology, Inc.",
    "full_name": "Pyxis Oncology, Inc.",
    "name_url": "stocks-analysis/pyxis-oncology-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "4.22",
    "chg": -0.1,
    "chgp": "-2.31%",
    "dir": -1,
    "prev_price": "4.32",
    "mcapval": "121.56",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US7473241013",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "836.14 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/pyxis-oncology-inc-1288050-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Pyxis Oncology, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-pyxis-oncology-inc-technically-bullish-or-bearish-3548056",
        "imagepath": "",
        "date": "2025-09-20 20:08:46",
        "description": "As of 5 September 2025, the technical trend for Pyxis Oncology, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed indicators influencing this position. The weekly MACD is bullish, while the RSI is bearish, indicating some divergence in momentum. Moving averages on the daily timeframe remain bullish, but the monthly KST is bearish, suggesting caution. Additionally, the Bollinger Bands show a bullish signal weekly but a mildly bearish signal monthly. \n\nIn terms of performance, the stock has significantly outperformed the S&P 500 over the past week and month, with returns of 24.73% and 87.1% respectively, but has underperformed over the past year with a return of -36.61% compared to the S&P 500's 17.14%. Overall, the mixed signals and recent trend change suggest a cautious approach...."
      },
      {
        "title": "Is Pyxis Oncology, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-pyxis-oncology-inc-overvalued-or-undervalued-3544225",
        "imagepath": "",
        "date": "2025-09-20 18:40:58",
        "description": "As of 14 August 2025, the valuation grade for Pyxis Oncology, Inc. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 0.81, an EV to EBIT of 0.25, and an EV to EBITDA of 0.26. In comparison to peers, Eton Pharmaceuticals, Inc. has a significantly higher EV to EBITDA of 187.8463, while Ocugen, Inc. shows an EV to EBITDA of -6.1838, highlighting Pyxis's relative valuation challenges.\n\nDespite a strong recent performance with a 1-month return of 87.1% compared to the S&P 500's 2.33%, the long-term outlook remains concerning, as the 1-year return of -36.61% starkly contrasts with the S&P 500's 17.14%. This suggests that while short-term gains may attract attention, the overall valuation metrics indicate that Pyxis Oncology, Inc. is currently overva..."
      }
    ],
    "total": 6,
    "sid": "1288050",
    "stock_news_url": "https://www.marketsmojo.com/news/pyxis-oncology-inc-1288050"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Pyxis Oncology, Inc. technically bullish or bearish?

2025-09-20 20:08:46

As of 5 September 2025, the technical trend for Pyxis Oncology, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed indicators influencing this position. The weekly MACD is bullish, while the RSI is bearish, indicating some divergence in momentum. Moving averages on the daily timeframe remain bullish, but the monthly KST is bearish, suggesting caution. Additionally, the Bollinger Bands show a bullish signal weekly but a mildly bearish signal monthly. In terms of performance, the stock has significantly outperformed the S&P 500 over the past week and month, with returns of 24.73% and 87.1% respectively, but has underperformed over the past year with a return of -36.61% compared to the S&P 500's 17.14%. Overall, the mixed signals and recent trend change suggest a cautious approach....

Is Pyxis Oncology, Inc. overvalued or undervalued?

2025-09-20 18:40:58

As of 14 August 2025, the valuation grade for Pyxis Oncology, Inc. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 0.81, an EV to EBIT of 0.25, and an EV to EBITDA of 0.26. In comparison to peers, Eton Pharmaceuticals, Inc. has a significantly higher EV to EBITDA of 187.8463, while Ocugen, Inc. shows an EV to EBITDA of -6.1838, highlighting Pyxis's relative valuation challenges. Despite a strong recent performance with a 1-month return of 87.1% compared to the S&P 500's 2.33%, the long-term outlook remains concerning, as the 1-year return of -36.61% starkly contrasts with the S&P 500's 17.14%. This suggests that while short-term gains may attract attention, the overall valuation metrics indicate that Pyxis Oncology, Inc. is currently overva...

View All News